Chemomab soars on positive data from trial of fatty liver drug

Chemomab Therapeutics

21/06/2023 12:34

** Shares of Chemomab Therapeutics  CMMB.O  rise 38% to
$2.40 premarket
    ** Co reports positive data from mid-stage trial of its
experimental drug CM-101 for treatment of a type of fatty liver
disease called non-alcoholic steatohepatitis (NASH)
    ** New data was in addition to results initially released in
January and showed that the treatment resulted in a greater
biomarker response in patients at greater risk of disease
progression than in those with lower risk disease or in
placebo-treated patients - CMMB
    ** Up to last close, stock had slumped ~46% YTD

 (Reporting by Aniruddha Ghosh in Bengaluru)
 ((Aniruddha.Ghosh@thomsonreuters.com; 91 83 83 81 2416;))